Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA7 | P43166 | 5/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 11/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487983 | 0.86 | PTGES2 (0.49) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2776043 | 0.86 | PTGES2 (0.47) | CA1CA2CA12CA7CA13 | |
| SCHEMBL3782946 | 0.86 | CA1 (0.45) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2791703 | 0.84 | PKM (0.47) | CA1CA2CA12CA7CA13 | |
| SCHEMBL3771716 | 0.84 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL13006836 | 0.84 | ACHE (0.44) | CA1CA2CA12CA7CA13 | |
| Trifluoroacetic Acid SCHEMBL30333105 | 0.84 | CA1 (0.42) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2776699 | 0.81 | PTGES2 (0.53) | CA1CA2CA12CA7CA13 | |
| SCHEMBL30586498 | 0.81 | PTGES2 (0.53) | CA1CA2CA12CA7CA13 | |
| SCHEMBL30605921 | 0.81 | CA12 (0.41) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-114614058-B | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | claimed |
| CN-114614058-A | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | claimed |
| CN-114432903-A | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-109438365-B | N- (3- ((4-trifluoromethyl) -2-pyrimidinyl) aminophenyl) -2, 6-difluorobenzenesulfonamide derivative | 华南师范大学 | 2022-04-05 | — | — | CN | claimed |
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | claimed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| US-20200099097-A1 | GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| CN-109761944-A | A kind of chrysin amide derivatives and preparation method thereof and medical usage | 武汉翼博济生生物科技有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | claimed |
| CN-107987071-A | The preparation method of melanoma new drug dabrafenib | 任伟 | 2018-05-04 | — | — | CN | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-4927452-A | 1-carbonyl-2-pyrazoline derivatives having herbicidal activity | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1990-05-22 | — | — | US | disclosed |
| EP-0269141-A2 | 1-Carbamoyl-2-pyrazoline derivatives having herbicidal activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | CA1 3540/4885CA2 2801/4885CA12 3903/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | CA1 3540/4885CA2 2801/4885CA12 3903/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | CA1 4705/4885CA2 4235/4885CA12 4841/4885 |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | BRAF, MAP2K1, MOK | CA1 1316/4885CA2 561/4885CA12 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.